Hepatitis B virus (HBV) infection is a worldwide public health problem. HBV-specific CD8+ CTLs are vital for viral clearance. Identification of immunodominant CTL epitopes from HBV-associated antigens is necessary for therapeutic vaccine development. We showed that the HLA-A*1101 allele is one of the most common alleles in both healthy individuals and chronic hepatitis B (CHB) patients in the Chongqing area, China. However, less than 10 % of epitopes of HBV-associated antigens have been identified in an HLA-A*1101 context. Here, we describe an immunodominant CD8+ T-cell response targeting a hepatitis B surface antigen determinant (HBs295–304) restricted by HLA-A*1101 in both healthy individuals and CHB patients. Moreover, HBs295–304 is more immunogenic for CTL induction than a known naturally HLA-A*1101-processed epitope from hepatitis B core antigen (HBc88–96). Therefore, the newly identified epitope, HBs295–304, will benefit the development of immunotherapeutic approaches for HBV infection.
Blockade of Tim-3 signaling restores the virus-specific CD8+T-cell response in patients with chronic hepatitis B
